Michael has 20 years of experience in Corporate Responsibility (CR), inclusive business, social innovation and integrity & compliance management, in business and academia.
He is currently the Head of Social Innovation & Strategy at Novartis. His accountabilities reach from the implementation of the Novartis CR and access to medicines strategy, inclusive business model innovation, innovative finance, ESG Investor Relations, measurement & evaluation, materiality analysis, Global Health policy etc. Since more than 10 years, Michael is a key partner for the business to develop and run social business models. He was a member of the team that developed the most current social business “Novartis Access” and since its inception more than 10 years ago, Michael is working with “Novartis Healthy Families”, a business that has broken even in India after 30 months, is now operating in a number of countries and has been featured in a HBS “Shared Value” case study from Michael Porter.
Previously, Michael had responsibilities for the development of the CR and access to medicines strategy of Novartis. He conducted the first materiality analysis of Novartis in 2006 that became an established management and investor relations instrument in the company. Michael also wrote the current Novartis Human Rights Guideline, developed a first framework to respond to the UN Guiding Principles on Business and Human Rights and is now being involved in developing the Human Rights Strategy and well as in conducting Human Rights Impact Assessments.
Michael was the Secretary of the CR Board of Novartis and is an author and editor of articles and books in the areas of CR, CR strategy, access to medicines, social entrepreneurship, integrity management, risk and good governance. Michael has a PhD with honors (summa cum laude) and was awarded for his academic work (PhD thesis) with the German Max Weber-Price for Business Ethics (2006).